MOTIVATION LETTER Addiction shortens human healthspan by accelerating biological aging through oxidative stress, neuroinflammation, and telomere attrition. The Conjunctive Consolidation Threshold model I developed and validated as an independent researcher in Lagos directly addresses this mechanism by preventing reward-memory encoding, the neural process that locks addictive behaviors into long-term storage. My three sole-authored preprints on OSF and Zenodo specify the tripartite pharmacological framework, its formal mathematical structure, and a Bayesian population dynamics simulation showing an 85.8 percent reduction in encoding probability from 0.855 to 0.122, with super-additivity of 12.8 percentage points. All five pre-registered hypotheses H1 through H5 were confirmed. VitaDAO funds decentralized longevity research that targets the fundamental biology of aging. My CCT model is a longevity-relevant intervention because it disrupts the memory consolidation pathway that makes addiction a chronic, relapsing condition, and chronic addiction is a documented driver of accelerated aging. I have built three open-source platforms that demonstrate my commitment to VitaDAO's open-science ethos: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions with a hERG cardiotoxicity MVP, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. My provisional patent on the CCT core architecture, filed Q3 2026, protects the invention while I pursue open publication. I am a Nigerian independent researcher, 29 years old, with a B.Pharm from the University of Ibadan and a German equivalent grade of 1.9. I seek VitaDAO funding to run preclinical validation experiments, extend the Bayesian MCMC simulations to human pharmacokinetic parameters, and build a community around decentralized longevity research from Africa. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I am ready to participate in VitaDAO governance, share my data and code openly, and demonstrate that independent researchers in LMIC settings can produce rigorous, translatable longevity science. RESEARCH STATEMENT The Conjunctive Consolidation Threshold model addresses a specific gap in addiction neuroscience and longevity research: no existing pharmacological intervention targets the moment of reward-memory encoding itself. Current treatments manage craving or block receptors after the memory is formed. My model proposes a tripartite intervention delivered at a precise temporal window, the conjunctive consolidation threshold, where dopamine, glutamate, and norepinephrine signaling converge to stabilize a reward memory. The formal mathematical specification on OSF (10.17605/OSF.IO/EMY4U) defines this threshold as a function of three neurotransmitter concentrations, receptor densities, and time since reward presentation. The Bayesian population dynamics simulation on Zenodo (10.5281/zenodo.20492472) used ODE/RK45 integration with PyMC MCMC sampling across 10,000 virtual subjects, varying pharmacokinetic parameters within human-relevant ranges. Encoding probability dropped from 0.855 to 0.122, a reduction of 85.8 percent. The super-additivity of 12.8 percentage points indicates that the tripartite combination outperforms any pairwise or single-agent intervention. This result is pre-registered and reproducible from my GitHub repository. For VitaDAO, the longevity relevance is direct: addiction accelerates biological aging through multiple pathways including oxidative damage from chronic drug metabolism, neuroinflammatory cascades that promote tau and amyloid pathology, and epigenetic changes that shorten telomeres. Preventing addiction consolidation is therefore a primary prevention strategy for aging-related neurodegeneration. My proposed workplan has three phases over 12 months. Phase one: extend the Bayesian model to incorporate human pharmacokinetic data from published clinical trials for each of the three candidate compounds, using my ADMET/QSAR pipeline and RDKit. Phase two: collaborate with my existing network to design a small-animal proof-of-concept study, using the CCT timing protocol derived from my mathematical specification. Phase three: publish the extended model and study protocol as a preprint, deposit all code and data on Zenodo, and present results to the VitaDAO community for governance feedback. My open-source platforms IMPRINT, TOPOLOGIX, and GATE demonstrate my ability to build and share computational tools. The provisional patent on CCT core architecture ensures that VitaDAO's investment is protected while the science remains open. I am an independent researcher in Lagos, Nigeria, with no institutional lab, yet I have produced validated computational results, secured endorsements from four leading computational neuroscientists, and built three functional platforms. VitaDAO funding would allow me to transition from computational validation to preclinical testing, establishing a pipeline that other LMIC researchers can replicate. SHORT ESSAY: OPEN SCIENCE COMMITMENT My entire research output is open. The three CCT preprints are on OSF and Zenodo with DOIs and CC-BY licenses. The code for the ODE/RK45 simulations, Bayesian MCMC sampling, and all figures is on my GitHub repository github.com/AmunRaPtah with a GNU General Public License. My platforms IMPRINT, TOPOLOGIX, and GATE are open-source under Apache 2.0. I have not published in a paywalled journal for this work. The review article under consideration at Neuroscience and Biobehavioral Reviews was submitted as a preprint first. I commit to depositing all data, code, and protocols from any VitaDAO-funded work on Zenodo with a CC-BY license within 30 days of generation. I will participate in VitaDAO governance by reviewing proposals from other researchers, contributing to community discussions on longevity research standards, and mentoring other LMIC independent researchers who want to adopt open-source computational methods. I have already done this informally: my GitHub repositories include documentation and tutorials for running the CCT simulations, and I respond to questions from other researchers within 48 hours. VitaDAO's decentralized model aligns with my practice of independent, transparent, reproducible science. SHORT ESSAY: DIVERSITY AND LMIC CONTRIBUTION I am a 29-year-old Nigerian independent researcher working from Lagos with no institutional affiliation, no PhD supervisor, and no dedicated lab. My computational infrastructure is a personal workstation and free-tier cloud credits. I have produced three preprints, three open-source platforms, a provisional patent, and a review article under review at a leading journal. This output demonstrates that rigorous longevity science can originate from LMIC settings when researchers have access to open tools and decentralized funding. VitaDAO's diversity and inclusion criteria explicitly value this kind of independent, geographically distributed work. My presence in the VitaDAO community would demonstrate that decentralized science is not a privilege of wealthy institutions. I will use any funding to build capacity in Nigeria: I will train two junior researchers in computational pharmacology using my platforms, publish all materials in English and in simplified formats for non-native speakers, and establish a local meetup group for DeSci and longevity research in Lagos. My collaborators at Michigan, Harvard, Princeton, and NYU have agreed to provide remote mentorship. This network, combined with VitaDAO funding, would create a replicable model for independent longevity research from Africa. CHECKLIST - [ ] Motivation letter, 300-500 words, written above - [ ] Research statement, 400-600 words, written above - [ ] Short essay on open science commitment, 200-350 words, written above - [ ] Short essay on diversity and LMIC contribution, 200-350 words, written above - [ ] CV or resume in VitaDAO's preferred format (to be prepared separately) - [ ] Links to three preprints on OSF and Zenodo with DOIs - [ ] Links to GitHub repositories for IMPRINT, TOPOLOGIX, GATE - [ ] ORCID profile (0009-0001-9272-6735) - [ ] Provisional patent filing number and date for CCT core architecture - [ ] Names and contact information for three references: Kent Berridge, Samuel Gershman, Nathaniel Daw - [ ] Confirmation of eligibility: independent researcher, no current PhD enrollment, Nigerian nationality - [ ] Wallet address for VitaDAO token-based grant distribution if applicable EDITOR NOTES - Eligibility risk: VitaDAO typically funds researchers with some institutional affiliation or PhD. Eniola has neither. The application must explicitly argue that his independent output and collaborator network substitute for institutional credentials. The essays above do this, but the reviewer may still flag it. - Fact to verify: The provisional patent filing date is listed as Q3 2026. Confirm that the patent has actually been filed or is at least in preparation with a confirmed filing number. If not filed, remove the claim. - Gap: The application does not specify the exact dollar amount requested. VitaDAO grants vary from 50k to 250k USD. Eniola should decide on a specific amount and justify it in the research statement or a budget section if VitaDAO requires one. The current draft leaves this open. - Gap: No mention of how Eniola will handle the time zone difference and asynchronous communication with a DAO that is primarily US- and Europe-based. A brief note on availability for governance calls and community discussions would strengthen the community engagement angle. - Fact to verify: The review article under review at Neuroscience and Biobehavioral Reviews. Confirm the journal name and submission status. If the article has been rejected or is at a different journal, update the text.